Phathom Pharmaceuticals Inc expected to post a loss of $1.08 a share - Earnings Preview

Phathom Pharmaceuticals

23/02/2024 14:31

* Phathom Pharmaceuticals Inc  PHAT.OQ   PHAT.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 26 (estimated) for the period ending December 31 2023
    * The Florham Park New Jersey-based  company is expected to
report
revenue of $412.33 thousand, according to the mean estimate from
6 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Phathom Pharmaceuticals
Inc is
for a loss of $1.08 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $26.00​, above​ its last closing price
of $10.47. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.87       -0.89      -0.76     Beat    14.7
 Jun. 30 2023  -0.94       -0.98      -0.84     Beat    14.2
 Mar. 31 2023  -1.23       -1.26      -0.89     Beat    29.4​
 Dec. 31 2022  -1.34       -1.35      -1.33     Beat    1.6
 ​​Sep.        -1.32       -1.32      -1.32     Met     -0.2
 30 2022                                                
 Jun. 30 2022  -0.99       -1.03      -1.33     Missed  -29.1​
 Mar. 31 2022  -0.98       -0.97      -1.07     Missed  -10.5
 Dec. 31 2021  -1.05       -1.03      -0.95     Beat    7.6
 This summary was machine generated February 23 at 14:31 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)